Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

ABSTRACT:

Background

In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to assess how the effects of empagliflozin would evolve after the discontinuation of the trial drug.

Methods

In the active trial, patients with chronic kidney disease were randomly assigned to receive either empagliflozin (10 mg once daily) or matching placebo and were followed for a median of 2 years. All the patients had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m² of body-surface area or an eGFR of at least 45 but less than 90 ml per minute per 1.73 m

SUBMITTER: EMPA-KIDNEY Collaborative Group 

PROVIDER: S-EPMC7616743 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature